# Shirley Clayton

> Shirley Clayton is a seed investor at REGiMMUNE backing Life Science. See 1 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: REGiMMUNE
- Total investments: 1
- Last investment: Feb 2016
- Lead investor: 100%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/shirley-clayton-97a3015

Shirley Clayton is a seed investor at REGiMMUNE focused on Life Science and Biotechnology. Prior to joining the board in February 2007, Ms. Clayton retired as President and Chief Executive Officer of Abmaxis, Inc., which was acquired by Merck & Co. As VP and Treasurer at Genentech, Inc., the first biopharmaceutical company, Ms. Clayton was actively involved in the early financing of the biotechnology industry. Prior to her role atAbmaxis, she co-founded Raven Biotechnologies, a cell biology company developing monoclonal antibody products, and served as its President and Chief Financial Officer. During her 25 years as an executive in the life science industry, Ms. Clayton was Chief Financial Officer, President or Chief Executive Officer in several companies including Protein Design Labs, now PDL BioPharma, Inc.; Cygnus, Inc., a drug delivery company; and CBYON, a medical technology company sold to GE Medical Systems. She is a member of the Board and Audit committee of Metro Bancorp and a member of the Board of Metro United Bank and Chairman of its Credit committee. Ms. Clayton received a BS in Chemistry from Smith College and an MBA from the Stanford University Graduate School of Business.

## Contacts

5 contacts available for Shirley Clayton: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/shirley-clayton?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Modalis Therapeutics | Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo. | $438.1K | Seed | Feb 17, 2016 |  |

1 of 1 investments shown.

## About REGiMMUNE

VC Fund · Tokyo, Japan

REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens throughinduction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

3 contacts available at REGiMMUNE.

| Name | Title | Profile |
| --- | --- | --- |
| Shirley Clayton | Board of Directors | https://shizune.co/investors/profile/shirley-clayton |
| Kenzo Kosuda | President and CEO of Certified Public Accountants | — |
| Yasuyuki Ishii | Co-Founder & Chairman | — |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [ANRI](https://shizune.co/investors/profile/anri) — VC Fund

## Featured in investor lists
- [Life Science Angel Investors in Japan](https://shizune.co/investors/life-science-angel-investors-japan)

## FAQ

### What does Shirley Clayton invest in?

Shirley Clayton invests primarily in Life Science and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Shirley Clayton?

Public channels for Shirley Clayton include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Shirley Clayton last invest?

The most recent investment recorded for Shirley Clayton closed in Feb 2016. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co